Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zimberelimab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Guangzhou Gloria Biosciences

06 Sep 2023 Status changed from not yet recruiting to recruiting, according to a Guangzhou Gloria Biosciences media release.
06 Sep 2023 According to a Guangzhou Gloria Biosciences media release, first patient dosing has been completed.
11 Apr 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com